MOXAVERINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21NO2.ClH
Molecular Weight	343.847
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCC1=CC2=CC(OC)=C(OC)C=C2C(CC3=CC=CC=C3)=N1

InChI

InChIKey=DULZSDGCXSLVAQ-UHFFFAOYSA-N

InChI=1S/C20H21NO2.ClH/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14;/h5-9,11-13H,4,10H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula	C20H21NO2
Molecular Weight	307.3862
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23203292 | https://clinicaltrials.gov/ct2/show/NCT00709449

Moxaverine, a derivative of papaverine, is a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma. In addition, it has been studied in phase II of the clinical trial for the treatment of ischemia. This compound is prohibited by FEI (International Federation of equine).

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 4 54 Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2854468	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Macular degeneration 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20456253	Primary	Phase III 665	Unknown Approved Use Unknown
Glaucoma 57 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20456253	Primary	Phase III 665	Unknown Approved Use Unknown
Ischemia 16 Sources: https://clinicaltrials.gov/ct2/show/NCT00569621	Primary	Phase II 1147	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
900 mg single, oral Highest studied dose\|Studied dose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23203292/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/23203292/	Sources: https://pubmed.ncbi.nlm.nih.gov/23203292/
150 mg single, intravenous Studied dose Dose: 150 mg Route: intravenous Route: single Dose: 150 mg Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M F Food Status: UNKNOWN Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x	Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x
150 mg single, intravenous Studied dose Dose: 150 mg Route: intravenous Route: single Dose: 150 mg Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M F Food Status: UNKNOWN Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x	Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x
150 mg single, intravenous Studied dose Dose: 150 mg Route: intravenous Route: single Dose: 150 mg Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x	Sources: https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2010.01878.x

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70882#section=Biological-Test-Results Page: 6.0	inconclusive [IC50 15.4871 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70882#section=Biological-Test-Results Page: 2.0	yes [IC50 1.7377 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70882#section=Biological-Test-Results Page: 6.0	yes [IC50 15.4871 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70882#section=Biological-Test-Results Page: 8.0	yes [IC50 17.3768 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70882#section=Biological-Test-Results Page: 3.0	yes [IC50 6.4476 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/70882#section=Biological-Test-Results Page: 9.0

PubMed

Title	Date	PubMed
Effect of systemic moxaverine on ocular blood flow in humans.	2009-11	18778333
Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma.	2005-06	15969638
Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion.	2004-12	15597400

Patents

Sample Use Guides

In Vivo Use Guide

intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

Using a combination of techniques to assess quantitatively the shape and the filterability of red blood cells (RBC) after exposure to stress conditions (400 mosmol/l, lactacidosis, pH 6.8), the effects of 1-benzyl-3-ethyl-6,7-dimethoxy-isoquinoline hydrochloride (moxaverine-HCl, Kollateral) were tested. The shape of freely suspended RBC was quantified using the tangent count procedure. Moxaverine, when present in doses between 10(-5) und 10(-2) mol/l while the RBC are stressed, restored both the normal discoid red cell configuration and the microrheological performance when tested under low shear stresses. The data showed that moxaverine exerted protective effects on RBC membrane curvature and whole cell microrheological behavior (performance).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:17:22 GMT 2025` Edited by `admin` on `Mon Mar 31 19:17:22 GMT 2025`
Record UNII	6R0I0E99CN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EUPAVERIN

Preferred Name

English

MOXAVERINE HYDROCHLORIDE

Common Name

English

1-BENZYL-6,7-DIMETHOXY-3-ETHYLISOQUINOLINE HYDROCHLORIDE

Systematic Name

English

MOXAVERINE HYDROCHLORIDE [MI]

Common Name

English

Moxaverine hydrochloride [WHO-DD]

Common Name

English

PAVERINE HYDROCHLORIDE

Common Name

English

KOLLATERAL

Brand Name

English

EUPAVERINA

Brand Name

English

MOXAVERINE HCL

Common Name

English

Code System Code Type Description

ECHA (EC/EINECS)

214-607-5